Since April 2009 Managing Partner of the Peppermint VenturePartners GmbH.
Having joined 3i in 2000, Klaus is partner and head of 3i Germany's healthcare venture capital team.
He has more than 12 years experience in the pharmaceutical industry as Senior Manager in Research and Business Development at Schering AG in Berlin and as Director of Business Development at ASTA Medica, a Degussa & Hüls group company in Frankfurt.Klaus specialises in healthcare investments including medtech across Europe.
He represented 3i on the board of Epigenomics AG, a company developing new molecular diagnostics towards personalised medicine, until January 2005, assisting with the IPO in 2004.
He is an active partner with supervisory board roles at Jerini AG, a company that is developing new small molecule therapeutics emerging from peptidic scaffolds, Combinature Biopharm AG and Elbion AG.
He is a member of LES (Licensing European Society) and is also a fellow of the Kellogg School of Management at Northwestern University in Chicago. Klaus holds a PhD in Biology and Pharmacology from the University of Mainz, Germany as well as an MBA from WHU / Kellogg Northwestern University in Chicago.